Pfizer climbs 4% on 2025 outlook

Evan David Seigerman, BMO analyst, joins ‘Closing Bell Overtime’ to talk Pfizer’s 2025 outlook.

Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *